February 2012 Archives

Brain Iron Imaging Study

| No Comments

Another MRI research study is evaluating brain iron and neuronal levels. Healthy participants or volunteers with PD ages 45-75 years of age are being recruited

Email: cnru@umn.edu or phone 612.624.7745

7T MRS in Parkinson's Disease

| No Comments

This study is looking for healthy controls and patients with Parkinson's (PD) to perform an MR scan.

The neurochemical profile of the SN of patients with PD as measured by high field MRS will differ from that of healthy controls, in that glutathione will be lower due to oxidative stress, lactate will be higher due to mitochondrial dysfunction, the gliosis markers myo-inositol and glutamine will be higher due to inflammation (glial activation) and N-acetylaspartate and glutamate will be lower due to neuronal loss/damage.
There will be a relationship between neurochemical changes and disease severity.

Contact: Susan Rolandelli, RN 612-624-7745 cnru@umn.edu

The investigators are interested in determining if the investigators are able to detect changes in brain chemistry using Magnetic Resonance Spectroscopy (MRS) in individuals with Parkinson's disease (PD), Gaucher's disease (GD), and those without these disorders when they are given the antioxidant N-acetylcysteine (NAC). This study will combine information from a medical history, a physical examination and disease rating scales with results obtained using MRS brain scans and pharmacokinetic studies from blood samples. This research will require 1 visit that will require about 4 to 5 hours of time. During this study, participants will provide their medical history, be examined and undergo a rating scale for about one hour; the brain scan and pharmacokinetic studies will require 1.5-2 hours of time; in total the study will take about 4-5 hours.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01427517

Contact: Sarah Hilbert, MS 612-624-7745 cnru@umn.edu

The purpose of this study is to determine if participants have changes in dopamine cells in their brain using DaTSCAN™ brain imaging. Dopamine cell loss occurs in Parkinson's disease (PD) and other degenerative Parkinsonian disorders, but does not occur in most other movement disorders such as essential tremor or dystonia. DaTSCAN, which is also known as 123I-Ioflupane, is a new compound that has been developed by General Electric, Inc. and has been approved by the US Food and Drug Administration (FDA) to help doctors detect changes in dopamine. This test is performed by injecting DaTSCAN into a vein in the arm, and after a few hours, a large amount of DaTSCAN temporarily accumulates in an area of the brain where there are a lot of dopamine brain cells. Because DaTSCAN contains a small amount of radioactive iodine, it allows doctors to use a special machine called single photon emission computed tomography (SPECT) scanning to detect the location and amount of radioactivity in the brain and help determine if there are changes in brain dopamine. It is hoped that this study will help doctors detect the presence of dopamine changes even before symptoms are present. This study will evaluate DaTSCAN in people with PD, those who are at risk for developing PD (e.g., those with idiopathic rapid eye movement sleep disorder (iRBD) and those who are heterozygous or homozygous for Gaucher's disease (GBA) mutations) and those who are healthy volunteers.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01358474

Contact: Christa Raszkowski 612.624.7745 cnru@umn.edu

About this Archive

This page is an archive of entries from February 2012 listed from newest to oldest.

Find recent content on the main index or look in the archives to find all content.